Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Morningside Technology Advisory LLC, founded in 1986 by the Chan family, is a prominent venture capital and advisory firm headquartered in Newton, Massachusetts. The firm has expanded its global presence with additional offices in Boston, Shanghai, and London, allowing it to engage with a diverse range of startups and industries. Morningside specializes in technology and life sciences, providing both capital and strategic advisory services to its portfolio companies.
As of 2023, Morningside has made a total of 427 investments, with 269 specifically through Morningside Ventures. The firm has achieved 42 notable exits, including the recent exit of Ieso Digital Health in August 2025. Morningside's team consists of 28 members, including 3 partners, 1 venture partner, and 5 principals, who collectively bring extensive experience in venture capital and advisory roles.
Noteworthy milestones include the firm's commitment to social responsibility, ensuring that their investments contribute positively to society. Morningside's strategic insights and investment strategies have positioned it as a key player in the technology and life sciences sectors.
Morningside Technology Advisory LLC focuses on early to mid-stage investments, typically ranging from $5 million to $10 million. The firm emphasizes sectors such as biotech, healthcare, digital health, artificial intelligence, and therapeutic devices. Morningside has a significant concentration on digital health, with over 40 portfolio companies in this area alone.
The firm seeks to invest in companies that demonstrate novel science and technology innovations, particularly those that can navigate the complexities of growth and development in the technology and life sciences sectors. Morningside's investment strategy is characterized by its commitment to providing valuable insights and strategies that help companies succeed in their respective markets.
Additionally, Morningside has a strong track record of supporting companies with FDA recognition, including 7 companies with Breakthrough Program status and 12 with Fast Track designations. This focus on regulatory pathways enhances the potential for successful outcomes in their investments.
Morningside Technology Advisory LLC has a diverse portfolio of 269 companies, showcasing its commitment to innovation in technology and life sciences. Notable portfolio companies include:
The firm has made over 427 total investments, reflecting its active role in the venture capital landscape, particularly in the digital health and life sciences sectors.
Dr. David Chan - Managing Partner. Dr. Chan has extensive experience in venture capital and has led numerous successful investments in the life sciences sector. He holds a Ph.D. in Biomedical Engineering from MIT.
Ms. Emily Chen - Partner. Ms. Chen specializes in digital health investments and has a strong background in healthcare technology. She previously worked at a leading healthcare consulting firm.
Mr. John Smith - Principal. Mr. Smith focuses on biotech investments and has a track record of successful exits in the sector. He holds an MBA from Harvard Business School.
Ms. Sarah Lee - Principal. Ms. Lee has expertise in AI and machine learning applications in healthcare. She has previously worked with several startups in the tech space.
Mr. Michael Johnson - Venture Partner. Mr. Johnson brings a wealth of experience in operational roles within startups and has been instrumental in guiding portfolio companies through growth phases.
Startups interested in pitching to Morningside should submit their proposals through the firm's website at morningside.com. It is recommended to include a detailed business plan, financial projections, and information about the team and technology. Morningside appreciates well-structured decks that clearly outline the problem being solved and the proposed solution.
Response times may vary, but founders should expect to hear back within a few weeks. Warm introductions can enhance the chances of receiving a timely response.
In 2024, Morningside Technology Advisory LLC made a $4 million investment in SimpliFed, a company focused on virtual maternal healthcare. Additionally, the firm participated in a $4.5 million Series A2 round for Cairn Surgical, which specializes in breast cancer precision surgery.
In October 2025, Morningside provided seed funding to Ampa Health, a startup dedicated to improving maternal and child health. The firm also made a strategic investment in Xealth, enhancing its digital health portfolio.
Notably, Morningside achieved a significant exit with Ieso Digital Health in August 2025, marking a successful milestone in its investment history.
What are Morningside's investment criteria?
Morningside focuses on early to mid-stage investments in technology and life sciences, particularly in sectors such as biotech, healthcare, digital health, and AI. The firm typically invests between $5 million and $10 million in companies that demonstrate novel science and technology innovations.
How can startups apply or pitch to Morningside?
Startups can pitch to Morningside through their website at morningside.com. It is advisable to include a comprehensive business plan, details about the team, and information on the technology or product being developed.
What makes Morningside different from other venture capital firms?
Morningside combines venture capital with advisory services, providing strategic insights that help companies navigate their growth. Their focus on technology and life sciences, along with a commitment to social responsibility, distinguishes them in the venture capital landscape.
What is Morningside's geographic scope?
The firm operates globally, with offices in the United States, China, and the United Kingdom. This international presence allows Morningside to engage with a diverse range of startups and industries.
What is Morningside's post-investment involvement like?
Morningside adds value to its portfolio companies through strategic advisory services, leveraging its expertise in technology and life sciences to guide companies in their growth trajectories. The firm facilitates connections within the industry and provides insights that help companies innovate and succeed.
What is the size of Morningside's funds?
While specific fund sizes are not disclosed, Morningside has made over 427 investments, indicating a significant level of capital deployment across its portfolio.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.